Stronger Warning Label Sought For Diabetes Drug Byetta

As deaths linked to the diabetes drug Byetta continue to climb, federal regulators are seeking a stronger warning label for the controversial drug. The FDA reported this week that they’ve receive six new reports of patients developing a dangerous form of pancreatititis while using Byetta. Two of those six have died. Byetta manufacturers Amylin Pharmaceuticals and Eli Lilly & Company have downplayed the news saying diabetics are already more prone to pancreatitis than the general non-diabetic population.
This week’s FDA announcement came on the heels of last October’s announcement that 30 Byetta patients had contracted the rare form of pancreatitis. More than 700,000 patients have used the injectable drug marketed for type 2 diabetes since it was first introduced on the market in 2005.